The Annual General Meeting of
The Company's income statement and balance sheet were adopted, and the Board members and the Chief Executive Officer were discharged from liability for the fiscal year 2022/2023. The Annual General Meeting approved the Board's proposal that no dividend be paid for the fiscal year 2022/2023.
Anders Essen-Möller,
Anders Essen-Möller was elected as Chairman of the Board and
The Annual General Meeting approved the proposed remuneration to Board members, the Chairman of the Board and the Vice Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company BDO until the end of the Annual General Meeting 2024. Principal auditor is the authorized public accountant Johan Pharmanson.
The Annual General Meeting resolved to authorize the Board, on one or more occasions prior to the next Annual General Meeting, to issue shares and/or warrants and to deviate from the shareholders' preferential rights when so doing. Payment may be made in cash, through a contribution or by offsetting. In a share issue for cash payment and in deviation from the shareholders' preferential rights, the number of shares and/or warrants issued pursuant to the authorization may not exceed 20 percent of the shares in the Company when the share issue occurs.
About
For further information, please contact:
Phone: +46 736 35 42 41
E-mail: ulf.hannelius@diamyd.com
Box 7349, SE-103 90
E-mail: info@diamyd.com Reg. no.: 556242-3797 Website: https://www.diamyd.com
Publication
The information was submitted for publication, through the agency of the contact person set out above, at 16.45 CET on
https://news.cision.com/diamyd-medical-ab/r/bulletin-from-annual-general-meeting-of-diamyd-medical-ab,c3886127
https://mb.cision.com/Main/6746/3886127/2467099.pdf
(c) 2023 Cision. All rights reserved., source